Serum Circulating MiRNA-342-3p As a Potential Diagnostic Biomarker in Parathyroid Carcinomas: A Pilot Study

Overview

Journal Endocrinol Diabetes Metab

Specialty Endocrinology

Date 2021 Sep 10

PMID 34505413

Citations 6

Authors

Julia Krupinova

Natalya Mokrysheva

Vasiliy Petrov

Ekaterina Pigarova

Anna Eremkina

Ekaterina Dobreva

Alina Ajnetdinova

Galina Melnichenko

Anatoly Tiulpakov

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the serum miRNA expression profiles between patients with benign and malignant parathyroid tumours.

Background: Despite recent advances in molecular biology, a histological tissue biopsy is still the method of choice used to diagnose most cancers. The preoperative cytology is not an applicable method for diagnosis of parathyroid cancer (PC); therefore, huge interest exists in terms of finding alternative methodologies to seek specific cancer biomarkers.

Design: A retrospective cross-sectional study.

Patients And Methods: Serum samples of patients with PC (n = 13) and parathyroid adenoma (PA) (n = 11), age (p = .999) and sex (p = .999) were matched and examined via the simultaneous comparative expression analysis of 754 microRNAs (miRNAs). The «TaqMan OpenArray Human MicroRNA Panel» (Applied Biosystems) was used to conduct real-time PCRs using the «QuantStudio 12К Flex» station (Life Technologies).

Results: According to the results of a pilot study, significant changes in expression levels between the PC group and the PA group (control) (p < .05) were observed for 17 miRNAs. Among them, the downregulation of miRNA-342-3p met the Benjamini-Hochberg adjustment criteria for multiple comparisons (p = .02).

Conclusions: Serum miRNA-342-3p could be a promising biomarker for PC to improve diagnosis and prognosis.

Citing Articles

[Primary hyperparathyroidism in children].

Benina A, Kolodkina A, Tiulpakov A, Kalinchenko N, Brovin D, Anikiev A Probl Endokrinol (Mosk). 2024; 70(3):74-82.

PMID: 39069775 PMC: 11334229. DOI: 10.14341/probl13382.

Circulating non-coding RNA biomarkers of endocrine tumours.

Butz H, Patocs A, Igaz P Nat Rev Endocrinol. 2024; 20(10):600-614.

PMID: 38886617 DOI: 10.1038/s41574-024-01005-8.

Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features.

Wang J, Jiang X, Wang Q, Zhao T, Shen H, Liu X Endocrine. 2024; 85(3):1357-1364.

PMID: 38730070 DOI: 10.1007/s12020-024-03831-2.

Parathyroid carcinoma: molecular therapeutic targets.

Marini F, Giusti F, Palmini G, Aurilia C, Donati S, Brandi M Endocrine. 2023; 81(3):409-418.

PMID: 37160841 DOI: 10.1007/s12020-023-03376-w.

MicroRNA Profile Alterations in Parathyroid Carcinoma: Latest Updates and Perspectives.

Wielogorska M, Podgorska B, Niemira M, Szelachowska M, Kretowski A, Siewko K Cancers (Basel). 2022; 14(4).

PMID: 35205624 PMC: 8869975. DOI: 10.3390/cancers14040876.

References

Rozenblatt-Rosen O, Hughes C, Nannepaga S, Shanmugam K, Copeland T, Guszczynski T . The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005; 25(2):612-20. PMC: 543415. DOI: 10.1128/MCB.25.2.612-620.2005. View

Wang L, Xu L, Xu M, Liu G, Xing J, Sun C . Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding. Cell Physiol Biochem. 2015; 35(6):2285-98. DOI: 10.1159/000374032. View

Bayraktar R, Bertilaccio M, Calin G . The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. Front Immunol. 2019; 10:1053. PMC: 6527596. DOI: 10.3389/fimmu.2019.01053. View

Lo W, Good M, Nilubol N, Perrier N, Patel D . Tumor Size and Presence of Metastatic Disease at Diagnosis are Associated with Disease-Specific Survival in Parathyroid Carcinoma. Ann Surg Oncol. 2018; 25(9):2535-2540. PMC: 8054302. DOI: 10.1245/s10434-018-6559-6. View

Newey P, Bowl M, Cranston T, Thakker R . Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum Mutat. 2010; 31(3):295-307. DOI: 10.1002/humu.21188. View

Anfossi S, Babayan A, Pantel K, Calin G . Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. 2018; 15(9):541-563. DOI: 10.1038/s41571-018-0035-x. View

Crippa E, Lusa L, De Cecco L, Marchesi E, Calin G, Radice P . miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. PLoS One. 2014; 9(1):e87039. PMC: 3903605. DOI: 10.1371/journal.pone.0087039. View

Kebebew E, Arici C, Duh Q, Clark O . Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001; 136(8):878-85. DOI: 10.1001/archsurg.136.8.878. View

Huang M, Qing Y, Shi Q, Cao Y, Song K . miR-342-3p elevates osteogenic differentiation of umbilical cord mesenchymal stem cells via inhibiting Sufu in vitro. Biochem Biophys Res Commun. 2017; 491(3):571-577. DOI: 10.1016/j.bbrc.2017.07.163. View

10.

Wang W, Han C, Sun Y, Chen T, Chen Y . Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. 2019; 12(1):55. PMC: 6556047. DOI: 10.1186/s13045-019-0748-z. View

11.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

12.

Cortez M, Anfossi S, Ramapriyan R, Menon H, Atalar S, Aliru M . Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2018; 58(4):244-253. PMC: 6368474. DOI: 10.1002/gcc.22725. View

13.

Mokrysheva N, Mirnaya S, Dobreva E, Maganeva I, Kovaleva E, Krupinova J . [Primary hyperparathyroidism in Russia according to the registry]. Probl Endokrinol (Mosk). 2020; 65(5):300-310. DOI: 10.14341/probl10126. View

14.

Spinelli C, Bonadio A, Berti P, Materazzi G, Miccoli P . Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest. 2000; 23(4):255-7. DOI: 10.1007/BF03343718. View

15.

Czimmerer Z, Varga T, Kiss M, Vazquez C, Doan-Xuan Q, Ruckerl D . The IL-4/STAT6 signaling axis establishes a conserved microRNA signature in human and mouse macrophages regulating cell survival via miR-342-3p. Genome Med. 2016; 8(1):63. PMC: 4886428. DOI: 10.1186/s13073-016-0315-y. View

16.

Kozomara A, Griffiths-Jones S . miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2013; 42(Database issue):D68-73. PMC: 3965103. DOI: 10.1093/nar/gkt1181. View

17.

Bollerslev J, Schalin-Jantti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R . MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019; 181(3):P1-P19. PMC: 6598862. DOI: 10.1530/EJE-19-0316. View

18.

Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F . A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10(6):R64. PMC: 2718498. DOI: 10.1186/gb-2009-10-6-r64. View

19.

Vaira V, Elli F, Forno I, Guarnieri V, Verdelli C, Ferrero S . The microRNA cluster C19MC is deregulated in parathyroid tumours. J Mol Endocrinol. 2012; 49(2):115-24. DOI: 10.1530/JME-11-0189. View

20.

Wei C, Harari A . Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012; 13(1):11-23. DOI: 10.1007/s11864-011-0171-3. View